Although studies have demonstrated the efficacy of the new anti-epileptic on the block, Pregabalin, in the treatment of Generalized Anxiety Disorder and Social Anxiety Disorder, there is no study so far of such efficacy for the treatment of depression. This case study in a patient with chronic major depression demonstrates that Pregabalin could be an effective augmenting agent to other anti-depressants, e.g. SSRI's and SNRI's. This added property of Pregabalin may be related to its probable GABA-ergic mechanism of action that could be soon the emerging treatment pathway for achieving better remission in chronic depression that is yet clinically problematic.
Frampton J.E., Foster R.H. (2006) Pregabalin: in the treatment of generalized anxiety disorder. CNSDrugs20: 685—693
2.
Krystal J.H., Sanacora G., Blumberg H., Anand A., Charney D.S., Marek G., Epperson C.N., Goddard A., Mason G.F. (2002) Glutamate and GABA systems as targets for novel antidepressant and mood-stabilizing treatments. Mol Psychiatry7: S71—80
3.
Pande A.C., Crockatt J.G., Feltner D.E., Janney C.A., Smith W.T., Weisler R., Londborg P.D., Bielski R.J., Zimbroff D.L., Davidson J.R., Liu-Dumaw M. (2003) Pregabalin in generalized anxiety disorder: a placebo-controlled trial. Am J Psychiatry160: 533—540
4.
Pande A.C., Feltner D.E., Jefferson J.W., Davidson J.R., Pollack M., Stein M.B., Lydiard R.B., Futterer R., Robinson P., Slomkowski M., DuBoff E., Phelps M., Janney C.A., Werth J.L. (2004) Efficacy of the novel anxiolytic pregabalin in social anxiety disorder: a placebo-controlled, multicenter study. J Clin Psychopharmacol24: 141—149
5.
Rickels K., Pollack M.H., Feltner D.E., Lydiard R.B., Zimbroff D.L., Bielski R.J., Tobias K., Brock J.D., Zornberg G.L., Pande A.C. (2005) Pregabalin for treatment of generalized anxiety disorder: a 4-week, multicenter, double-blind, placebo-controlled trial of pregabalin and alprazolam. Arch Gen Psychiatry62: 1022—1030
